Pharmicell Expands Managed Cell Types to Accelerate CDMO Business for Cell Therapies

On May 27, Pharmicell announced that it has completed the expansion of its scope of managed cell types for human cell management operations, in order to broaden its contract development and manufacturing organization (CDMO) business for cell therapies.

With the addition of new cell types, Pharmicell can now handle a total of seven types of cells, including bone marrow-derived mononuclear cells, as well as autologous and allogeneic bone marrow, adipose tissue, and umbilical cord-derived mesenchymal stem cells (MSCs). This significantly strengthens the company's capabilities in cell manufacturing and supply. As a result, Pharmicell has established a foundation to fully launch its CDMO business targeting advanced regenerative medicine institutions.

In addition to manufacturing and supplying cells, Pharmicell also provides contract testing services, including sterility testing, mycoplasma negativity testing, and exogenous virus negativity testing. By offering these services, Pharmicell has secured a differentiated competitive edge as a CDMO partner with a comprehensive quality management system.

With over 20 years of experience in stem cell therapy production and quality management, Pharmicell is equipped with advanced GMP manufacturing facilities, a production infrastructure based on human cell management operations, skilled professionals, and a well-established testing and evaluation system. Leveraging these strengths, Pharmicell is positioning itself as a specialized CDMO institution that covers the entire cycle, from early-stage research and development to clinical trials and commercialization.

A Pharmicell representative stated, "We plan to continue providing comprehensive support to advanced regenerative medicine institutions, including clinical research, development of cell therapy manufacturing processes, establishment of quality management systems, and therapeutic consulting." The representative added, "We will actively utilize our specialized mesenchymal stem cell culture medium, PharmiSTEM hMSC Media, to accelerate our efforts to secure a leading position in the growing advanced regenerative medicine market."

Pharmicell intends to further strengthen its role as a strategic partner in the domestic and global advanced regenerative medicine industry, based on its advanced manufacturing system and quality management capabilities.

This content was produced with the assistance of AI translation services.